If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGooch & Housego Regulatory News (GHH)

Share Price Information for Gooch & Housego (GHH)

Share Price is delayed by 15 minutes
Get Live Data
852.00    -30.00 (-3.40%)
Bid:
850.00
Ask:
856.00
Spread: 6.00 (0.706%)
Market Cap: £233.20m
GHH Live PriceLast checked at - London Stock Exchange

Intraday Gooch & Housego Share Chart

Half Year Trading Update

7 Apr 2020 07:00

RNS Number : 9782I
Gooch & Housego PLC
07 April 2020
 

For immediate release

7 April 2020

 

 

Gooch & Housego PLC

("G&H" or the "Company")

 

Half Year Trading Update

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, provides an update on trading in the six months to 31 March 2020.

Trading

Trading in the six months reflected trends that we have previously reported, including more recently an impact from the COVID-19 emergency.

Industrial laser demand remained at below 'normalised' levels, but orders for fibre optics, hi-reliability fibre couplers for undersea cables and our A&D and life science capabilities continued at a good level. In general we are now seeing improved demand from Japan, S.Korea and to an extent from China, but a push back of orders from some of our US and European customers.

Improved industrial laser demand will ultimately be driven by technical innovation such as 5G and new laser based manufacturing techniques. A&D and life sciences are more stable with areas of life sciences driving extra demand.

Overall trading in the first half of FY 2020, which was weighted more toward fibre optics, A&D and life sciences, is expected to have been lower than the same time prior year.

As at 31 March 2020 our order book was at £91.7 million (31 March 2019: £93.2 million), which represents a reduction on the same time last year of 1.7%, or 4.9% on a constant currency basis.

Priorities in the COVID-19 emergency

Our primary concern during the emergency is the health and safety of our staff, customers and suppliers. Wherever possible our employees are working from home and for those that need to work at our manufacturing sites we have implemented a range of new health and safety measures to ensure that we rigorously meet social distancing and cleanliness requirements and other relevant guidelines and regulations.

Our teams have been responsive and agile in the rapidly developing situation and we are working hard to ensure we continue to support our customers' products and programmes, many of which are classified as essential products and services.

Manufacturing capacity

As previously reported, four of our six manufacturing sites in the US are open as they are exempt from State wide 'stay at home' orders. The remaining two, Fremont and Cleveland are aiming to operate at around 50% of 'normal' capacity levels, which is an improvement on the temporary closures announced last month.

In the UK all of our five manufacturing sites are open though the unique nature of our Torquay facility is such that it will need to operate at a reduced capacity in order to rigorously adhere to the Government's COVID-19 guidelines. ITL is now operating at near to full capacity. This is due to increased demand for medical diagnostic kits and a unit which improves respiratory function and oxygen supply, as part of a ventilator system for patients in critical care, including those with COVID-19.

Cost control

Management has implemented a number of measures to control cash and costs. These measures are consistent with retaining a highly skilled workforce and maintaining the Group's infrastructure and capabilities to enable future growth post the COVID-19 emergency.

Financial strength

The Company remains in a good financial position with a strong balance sheet and good levels of available cash. We have recently completed an amendment to our existing credit facility, giving a total facility of $50 million until April 2023.

Outlook

It is uncertain how long the current COVID-19 emergency will last, but there is likely to be a material short term impact on G&H. We have previously indicated an expected increased H2 weighting to this year's trading performance, with the potential for revenue and profit to move into the Group's next financial year. A greater A&D and life science weighting is anticipated.

The Company is fundamentally sound and there is long term growth potential in each of our chosen sectors. We will continue to invest in novel, cutting edge photonic technologies. As such G&H remains well placed to take advantage of the recovery when it comes.

Mark Webster, Chief Executive Officer of Gooch & Housego, commented:

"Trading in the half year has continued along previously reported lines, including an impact from the COVID-19 emergency. Our order book remains at a good level for fibre optics, fibre couplers for undersea cables and A&D and life sciences.

"G&H is proud that in the US most of our product lines are considered to be vital for essential services and national security, enabling sites to stay open under 'stay at home orders'. In the UK all sites are open, albeit with Torquay operating at reduced capacity. We continue to manufacture critical components for industrial lasers, laser systems, telecom, A&D and life science products.

"We believe the current COVID-19 emergency has validated our long term strategy of diversification and moving up the value chain."

 

 

For further information contact: -

 

Mark Webster/Chris Jewell

Gooch & Housego PLC

01460 256440

Mark Court/ Charlotte Slater

Buchanan

020 7466 5000

Chris Baird/Patrick Robb/

David Anderson

Investec Bank plc

020 7597 5970

 

Notes to editors

 

1. Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2. All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events. These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements. Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTVQLFBBZLEBBV
Date   Source Headline
21st Dec 202210:02 amRNSPosting of Annual Report and Notice of AGM
20th Dec 202212:30 pmRNSDirector/PDMR Shareholding
6th Dec 20224:26 pmRNSDirector/PDMR Shareholding
6th Dec 20229:38 amRNSDirector/PDMR Shareholding
6th Dec 20227:00 amRNSResults for the year ended 30 September 2022
25th Nov 20223:17 pmRNSHolding(s) in Company
23rd Nov 20224:27 pmRNSHolding(s) in Company
18th Nov 20222:20 pmRNSHolding(s) in Company
2nd Nov 20227:00 amRNSNotification of Full Year Results
27th Oct 202212:56 pmRNSHolding(s) in Company
18th Oct 20222:50 pmRNSHolding(s) in Company
26th Aug 20221:00 pmRNSDirector/PDMR Shareholding
19th Aug 202212:24 pmRNSNotification of Major Holdings
19th Aug 202212:19 pmRNSNotification of Major Holdings
17th Aug 202212:00 pmRNSDirector/PDMR Shareholding
17th Aug 202211:57 amRNSDirector/PDMR Shareholding
17th Aug 202211:54 amRNSDirector/PDMR Shareholding
17th Aug 20227:00 amRNSTrading Update and Directorate Changes
13th Jun 202212:58 pmRNSHolding(s) in Company
7th Jun 20227:00 amRNSInterim Results
23rd May 20224:41 pmRNSSecond Price Monitoring Extn
23rd May 20224:36 pmRNSPrice Monitoring Extension
11th May 20227:00 amRNSNotification of Half Year Results
5th Apr 20227:00 amRNSHalf Year Trading Update
23rd Feb 20221:11 pmRNSResult of AGM
23rd Feb 20227:00 amRNSAGM Trading Update
9th Feb 20224:35 pmRNSPrice Monitoring Extension
13th Jan 20227:00 amRNSGrant of LTIP Awards
12th Jan 202212:18 pmRNSHolding(s) in Company
30th Dec 20214:41 pmRNSSecond Price Monitoring Extn
30th Dec 20214:36 pmRNSPrice Monitoring Extension
17th Dec 20217:00 amRNSPosting of Annual Report and AGM Notice
30th Nov 20217:00 amRNSResults for the year ended 30 September 2021
17th Nov 20217:00 amRNSNotification of Full Year Results
25th Oct 20214:41 pmRNSSecond Price Monitoring Extn
25th Oct 20214:35 pmRNSPrice Monitoring Extension
5th Oct 20217:00 amRNSFull Year Trading Update
18th Aug 20217:00 amRNSDiversity Underpins Competitive Advantage
27th Jul 202112:20 pmRNSUpdate on 2021 AGM Resolutions
9th Jun 20213:58 pmRNSPosting of Interim Report
3rd Jun 20217:00 amRNSHolding(s) in Company
1st Jun 20217:00 amRNSInterim Results
10th May 20217:00 amRNSNotification of Half Year Results
28th Apr 20213:20 pmRNSHolding(s) in Company
7th Apr 20217:00 amRNSHalf Year Trading Update
26th Mar 20217:00 amRNSGrant of SAYE Options
12th Mar 20217:00 amRNSAppointment of Non-Executive Director
11th Mar 20214:59 pmRNSPCA to the Chairman Share Purchase
24th Feb 20211:01 pmRNSResult of AGM
24th Feb 20217:00 amRNSAGM Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.